Bowhead Specialty Holdings Inc. (BOW) stock intrinsic value fair value estimate & owner earnings analysis

Bowhead Specialty Holdings is a young specialty property and casualty insurer (started 2018, public since 2024) that writes hard-to-place liability risks through four divisions: Casualty (mainly excess casualty), Professional Liability, Healthcare Liability and Baleen Specialty (small-business risks handled by a digital underwriting model). About 80% of premium is non-admitted (E&S) business sold through wholesale brokers. It has no insurance ratings of its own, so every policy is issued on American Family (AmFam) paper and 100% reinsured back to Bowhead's own insurance company in exchange for a ceding fee. AmFam owns about 14.3% of the shares. How we measured earnings. For an insurer, operating cash flow is inflated by growth in loss reserves and unearned premium, which is other people's money held temporarily, not profit. We stripped those balance-sheet movements out, deducted stock compensation and the non-cash warrants granted to AmFam as real costs, and deducted maintenance capital spending. On that basis earnings per diluted share were about $0.23 (2022), $0.75 (2023), $1.09 (2024) and $1.36 (2025); the result reconciles to reported net income plus non-cash items. Because interest is an ordinary cost for an insurer, we valued earnings after interest and did not subtract the company's debt separately. We measured the business from 2025, the first full year at its current scale after the mid-2024 IPO (median of 2024-2025 is $1.22, and 2025 alone is $1.36). The first half of 2026 (net income $32.1M against $23.8M a year earlier, with Q1 and Q2 both about $16M) corroborates the higher level. What is in the bag. (1) Premium already written but not yet earned: 2025 net written premium of $558M exceeded net earned premium of $492M, so about $66M more premium flows into 2026 revenue even if no new policy is written. (2) Invested assets already on the balance sheet: fixed-maturity holdings rose from $880M to $1.37B during 2025 and net reserves grew from $510M to $748M, so investment income (about $58M in 2025, more than three times underwriting profit) will run well above 2025 without new business. Trailing owner-earnings growth in 2025 was about 25%; our base case assumes about 26% in 2026, which is consistent with the earned-premium and invested-asset step-up above and the first-half 2026 results, and then no further growth. We did not credit further premium growth, share gains, or expense-ratio improvement in the base case: the company has grown premium 24-28% a year but only in a hard insurance market, and it warns that rates are already softening in professional liability and D&O and that the market could soften more broadly. Costs locked in. AmFam's ceding fee steps up from 2.75% to 3.25% of net premiums on May 23, 2026 and to 5.0% on May 23, 2027, roughly $14M a year of extra pre-tax cost at today's premium volume; the combined ratio was 96.5% in 2025, so this eats most of the underwriting margin. In November 2025 the company also issued $150M of 7.75% senior notes due December 2030 (about $12M a year of interest, versus about $1M in 2025). All cases include both. Base case (about $21.50 per share). Earnings of roughly $1.70 per share in 2026 easing to about $1.62 in 2027-28 as the fee step-up lands, then about $1.67 as float income keeps building on long-tail reserves, held flat through 2035. Earnings then fade to zero over the following ten years as the reserve book pays out, with the statutory capital behind it returned to shareholders (about $14 of equity per share today). The business is worth about $21.50 per share on a basis that already has the notes' interest deducted; the notes' $150M principal is treated as a liability of a lender-funded holding company and assumed refinanced at similar terms in 2030. Bear case (about $11.20 per share). Reserves rest largely on industry patterns because the company has little loss history of its own, and the loss ratio already rose 2.3 points in 2025 as Casualty grew as a share of the book and expected loss ratios were raised for Professional and Healthcare Liability. The bear case repeats that deterioration twice (loss ratio to 71%), assumes premium falls about 5% a year for two years as pricing softens (which management already sees in parts of the book), takes a one-time reserve strengthening of about 4% of net reserves (about $30M pre-tax) in 2028, and returns only half of the capital in the fade. Earnings fall to about $0.86 per share. The business is worth about $11.20 per share, after interest on the notes; the notes remain refinancing-dependent in 2030 but interest is covered by investment income in this case. Bull case (about $28.30 per share). The company's demonstrated levers execute: loss ratio returns to about 65.5% (2024 was 64.4%), operating expenses grow at about 60% of premium growth (they grew 15% against premium growth of 28% in 2025), and premium grows 6% a year for five years, a quarter of the recent pace, with 80 cents of surplus retained for each dollar of added premium. Earnings reach about $3.05 per share by the early 2030s. We did not credit a return to 20%+ premium growth or new lines, which are not yet evidenced. What would make this wrong. Higher than expected loss costs on the 2023-2025 accident years would reduce every case, since reserves are built on limited company-specific data. Loss of the AmFam relationship would be severe: the filing states the company could write only a de minimis amount of business on its own paper without a standalone rating, and the contracts can be terminated in certain circumstances. A faster softening in casualty pricing would hit both premium and margins. On the other side, continued hard-market conditions and operating leverage could push earnings above the bull case. Some reserve adequacy points cannot be verified from the filings because the company has only a few years of its own claim history. On our reading, the shares are worth about $21.50 in the middle case, with a plausible range of about $11 to $28. The margin-of-safety price is well below that, near $13, which allows for the thin underwriting margin, limited loss history and dependence on one carrier partner.